

Antibiogram 7/1/2021 to 6/30/2022

Gram Positive	% Sensitive	E. faecalis	E. faecium	MRSA	MSSA	S. epidermidis	S. pneumoniae	Strep agalactiae (Group B)
# Isolates		126	3	651	499	215	134	67
Ampicillin		100	33	X	X	X	X	100
Penicillin		100	33	0	0	0	49	100
Oxacillin		**	**	0	100	33	N/A	N/A
Ciprofloxacin		94	33	43	90	77	*	N/A
Levofloxacin		95	33	45	91	78	100	98
Vancomycin		100	33	100	100	100	100	100
Clindamycin		**	**	68	75	57	79	26
Erythromycin		8	0	15	64	25	40	20
Inducible Clindamycin absent (% S)		N/A	N/A	96	78	93	98	82
Cefotaxime		**	**	0***	100***	33***	94	100
Ceftriaxone		**	**	0***	100***	33***	95	100
SMX-TRI		**	**	98	96	64	71	N/A
Linezolid		100	100	100	100	100	100	N/A
Quinup/Dalfo		**	**	100	100	100	N/A	N/A
Strept Synergy		93	100	N/A	N/A	N/A	N/A	N/A
Gent Synergy		93	100	N/A	N/A	N/A	N/A	N/A

\*No CLSI guidelines for susceptibilities

\*\*Intrinsically resistant

\*\*\* Deduced based on Oxacillin/Cefoxitin screen

N/A - not applicable

X - place holder; not tested on organism

Improving trend

Worsening trend

Antibiogram 7/1/2021 to 6/30/22

**Gram Negative rods**      **% Sensitive**

	E coli	E. cloacae complex	Kleb pneumoniae	Klebsiella oxytoca	P mirabilis	P aeruginosa	S. marcescens	Shigella sonneii	Salmonella species	Acinetobacter baumannii	H. influenzae
# isolates	1685	85	165	76	128	338	72	1	27	24	226
Amikacin	99	100	98	100	100	96	100	*	*	***	X
Amoxicillin/Clav	X	**	X	X	X	**	**	X	X	**	89
Ampicillin	55	**	**	**	94	**	**	100	89	**	36
Ampicillin/Sulbact	58	**	84	82	99	**	**	100	89	90	X
Cefazolin	93	**	92	89	100	**	**	*	*	0	X
Ceftazidime	94	87	94	95	99	87	99	100	96	90	92
Ceftriaxone	94	100	93	95	99	**	79	100	100	0	98
Ciprofloxacin	90	96	95	97	96	89	99	100	100	100	100
ESBL Negative	95	N/A	94	95	X	N/A	N/A	N/A	N/A	N/A	N/A
Gentamicin	92	99	97	99	99	86	100	*	*	100	X
Imipenem	100	100	100	100	97	88	X	X	100	100	X
Levofloxacin	85	89	91	93	94	77	90	X	100	95	X
Meropenem	99	100	100	100	100	89	100	X	X	90	100
Nitrofurantoin <sup>4</sup>	95	39	30	91	**	**	**	100	85	X	X
Pipercillin/Tazo	99	93	94	97	100	91	***	***	***	90	X
SMX/TRI	80	82	89	92	90	**	X	0	100	X	59
Tobramycin	92	97	95	97	100	96	96	*	*	100	X

X - Place holder/not tested

N/A - Not applicable

\* - Aminoglycosides, first- and second-generation cephalosporins, and cephamycins may appear active *in vitro* , but are not effective clinically, should not be reported.

\*\* - Intrinsically resistant

\*\*\* Not reported for these organisms on Vitek.

1: Includes *E coli* with Extended Beta Lactamase Spectrum (ESBL)

2: Includes *Klebsiella* with Extended Beta Lactamase Spectrum (ESBL)

3: *Proteus mirabilis* can be intermediate or resistant to imipenem due to other mechanisms than carbapenemases; is intrinsically resistant to Polymyxin B, Colistin, and Tetracyclines.

4: For use in Urine only

5: Kirby-Bauer susceptibilities

Improving trend

Worsening trend